GILEAD SCIENCES INC

GILD represents Gilead Sciences, Inc., a biopharmaceutical company headquartered in Foster City, California. The company focuses on researching, developing, and commercializing innovative medicines, particularly in areas such as HIV, viral hepatitis, and oncology. Gilead is known for its portfolio of antiviral therapies and has expanded into cell therapy and other therapeutic areas through acquisitions and internal research. Its stock trades on the Nasdaq under the ticker GILD.

Recent performance of GILD stock can vary based on market conditions, company news, and broader sector trends. For the most current price changes and performance metrics, please refer to the latest data displayed on this page. Historical price movements and percentage changes are updated regularly to reflect the most recent trading sessions.

Evaluating GILD's valuation involves examining metrics such as the price-to-earnings (P/E) ratio, price-to-sales (P/S), and enterprise value-to-EBITDA, and comparing them to peers in the biopharmaceutical industry. Analysts also consider growth prospects, pipeline strength, and profitability. Because valuation depends on current market data, refer to the latest figures on this page for accurate ratios and comparisons.

Yes, GILD stock can be traded outside regular U.S. market hours through extended-hours trading sessions, such as pre-market and after-hours. However, liquidity may be lower, and spreads can be wider, leading to increased volatility. Not all brokers offer extended-hours trading, and eligibility requirements may apply. Investors should check with their brokerage for specific availability and risks.

Gilead Sciences pays a quarterly dividend to shareholders. The company has a history of returning capital through dividends and share repurchases. Dividend amounts and yields can change over time based on company decisions and financial performance. For the latest dividend rate and yield, please see the dividend section on this page.

Key risks for GILD include pipeline failures in clinical trials, regulatory setbacks, patent expirations leading to generic competition, and pricing pressures in the pharmaceutical industry. The company also faces risks related to product concentration, litigation, and changes in healthcare policy. Economic conditions and foreign exchange fluctuations can impact international sales. Investors should review Gilead's SEC filings for a comprehensive risk discussion.